Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity

Paratek Pharmaceuticals (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today presented a new analysis of the Phase 3 OPTIC study of omadacycline, its first in class aminomethylcycline, versus moxifloxacin, a fluoroquinolone, for the treatment of community-acquired bacterial pneumonia (CABP). OPTIC efficacy results were presented by measures of disease severity.

As quoted in the press release:

The data showed similar, high rates of response for the early clinical response (ECR) and post therapy evaluation (PTE, also known as test-of-cure) endpoints in both the omadacycline and moxifloxacin treatment groups, regardless of the severity of disease. The results were presented today as an oral session at the American Thoracic Society 2018 International Conference.

“This analysis underscores that across the range of disease severity studied, omadacycline demonstrated high rates of clinical success at the early response timepoint, in hospitalized CABP patients.  The implications for clinical practice are that achieving clinical success at an early timepoint could potentially result in transition from intravenous to oral omadacycline allowing for hospital discharge,” said Paul McGovern, Vice President of Clinical Affairs, Paratek. “Omadacycline, if approved, will provide physicians with a new option to treat patients with CABP.”

Click here to read the full press release.